Evidence map›Paper›PMID 28187754›Full record

ArticleBMC infectious diseases2017

Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.

M M P S C Fernando, W A N V Luke, J K N D Miththinda, R D S S Wickramasinghe, B S Sebastiampillai, M P M L Gunathilake, F H D S Silva, R Premaratna

Abstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Prevalence of Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Antibiotic Resistance Pattern of Extended Spectrum Beta Lactamase ProducingFrontiers in cellular and infection microbiology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M M P S C FernandoProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
W A N V LukeDepartment of Clinical Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka. nathashaluke@gmail.com.
J K N D MiththindaProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
R D S S WickramasingheProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
B S SebastiampillaiProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
M P M L GunathilakeProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
F H D S SilvaProfessorial Medical Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka.
R PremaratnaDepartment of Medicine, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtended Spectrum Beta- Lactamase producing organisms causing urinary tract infections (ESBL-UTI) are increasing in incidence and pose a major burden to health care. While ESBL producing Klebsiella species seem to account for most nosocomial outbreaks, ESBL-producing E. coli have been isolated from both hospitalized and non-hospitalized patients. Although 95-100% ESBL organisms are still considered sensitive to meropenem, rapid emergence of carbapenem resistance has been documented in many countries. The objective of this study was to evaluate urinary tract infections caused by ESBL producers and the antibiotic susceptibility patterns in Sri Lanka.

methodsPatients with confirmed ESBL-UTI admitted to Professorial Medical Unit, Colombo North Teaching Hospital from January - June 2015 were recruited to the study. Their urine culture and antibiotic susceptibility reports were evaluated after obtaining informed written consent.

resultsOf 61 culture positive ESBL-UTIs, E. coli caused 53 (86.8%), followed by Klebsiella in 8 (13.1%).30 (49.1%) had a history of hospitalization within the past three months and included 6/8(75%) of Klebsiella UTI and 24/53(45.2%) of E.coli UTI. Antibiotic susceptibility of ESBL organisms were; Meropenem 58 (95%), Imipenem 45 (73.7%), Amikacin 37 (60.6%) and Nitrofurantoin 28(45.9%). In 3(4.9%), E.coli were resistant to Meropenem. These three patients had received multiple antibiotics including meropenem in the recent past for recurrent UTI.

conclusionsWe observed a higher percentage of E. coli over Klebsiella as ESBL producing organisms suggesting most ESBL-UTIs to be community acquired, Carbapenems seem to remain as the first line therapy for majority of ESBL-UTIs in the local setting. However 4.9% prevalence of meropenem resistance is alarming compared to other countries. Although prior antibiotic utilization and hospitalization may contribute to emergence of ESBL producing Klebsiella and E.coli in Sri Lanka, high prevalence of community acquired ESBL-E. coli needs further investigations to identify potential causes . Being a third world country with a free health care system, observed alarming rate of carbapenem resistance is likely to add a significant burden to health budget. We feel that treatment of infections in general needs a careful approach adhering to recommended antibiotic guidelines in order to prevent emergence of multi drug resistant organisms.

Indexed as

Anti-Infective Agentsbeta-LactamasesCarbapenemsCross InfectionCross-Sectional StudiesEscherichia coliEscherichia coli InfectionsFemaleHospitals, TeachingHumansIncidenceKlebsiellaKlebsiella InfectionsMaleMicrobial Sensitivity TestsMiddle AgedAnti-Infective Agentsbeta-LactamasesCarbapenemsCarbapenem resistanceESBL producersUrinary tract infections

Identifiers

PMID28187754
PMCPMC5303299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.